| Modelling the cardiovascular effects of ephedrine AM Persky, NS Berry, GM Pollack, KLR Brouwer British journal of clinical pharmacology 57 (5), 552-562, 2004 | 68 | 2004 |
| Personal digital assistant‐based drug reference software as tools to improve rational prescribing: Benchmark criteria and performance BC Knollmann, BJ Smyth, CE Garnett, AN Salesiotis, DM Gvozdjan, ... Clinical Pharmacology & Therapeutics 78 (1), 7-18, 2005 | 25 | 2005 |
| Efficacy and Tolerability Exposure–Response Relationship of Retigabine (Ezogabine) Immediate-Release Tablets in Patients With Partial-Onset Seizures DJ Tompson, CS Crean, R Reeve, NS Berry Clinical therapeutics 35 (8), 1174-1185. e4, 2013 | 14 | 2013 |
| Rheumatoid arthritis disease progression modeling R Reeve, L Pang, B Ferguson, M O’Kelly, S Berry, W Xiao Therapeutic Innovation & Regulatory Science 47 (6), 641-650, 2013 | 10 | 2013 |
| Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20%(Ig20Gly) in patients with primary … T Dumas, NS Berry, M Wolfsegger, S Jolles, B McCoy, L Yel International Immunopharmacology 71, 404-410, 2019 | 8 | 2019 |
| Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in Pseudomonas fluorescens (JZP‐458) T Lin, T Dumas, J Kaullen, NS Berry, MR Choi, K Zomorodi, JA Silverman Clinical Pharmacology in Drug Development 10 (12), 1503-1513, 2021 | 6 | 2021 |
| Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20gly) loading and maintenance dosing regimens in immunoglobulin-naïve … Z Li, T Dumas, NS Berry, B McCoy, L Yel International Immunopharmacology 100, 108044, 2021 | 4 | 2021 |
| Benefits of model-based drug development: a rigorous, planned case study R Reeve, S Berry, W Xiao, B Ferguson, M Thürk, R Goetz Communications in Statistics-Simulation and Computation 44 (9), 2210-2222, 2015 | 3 | 2015 |
| Critical evaluation of handheld electronic prescribing guides for physicians FD Min, B Smyth, N Berry, H Lee, BC Knollmann Clinical Pharmacology & Therapeutics 75 (2), P92-P92, 2004 | 3 | 2004 |
| Use of statistical and pharmacokinetic–pharmacodynamic modeling and simulation to improve decision-making: A section summary report of the trends and innovations in clinical … H Kimko, S Berry, M O’Kelly, N Mehrotra, M Hutmacher, V Sethuraman Journal of Biopharmaceutical Statistics 27 (3), 554-567, 2017 | 2 | 2017 |
| Lifecycle modeling and simulation in clinical trials A Garrett, M O'Kelly, D Walp, NS Berry Applied Clinical Trials 24 (6/7), 30, 2015 | 2 | 2015 |
| Electrical Computing Devices Providing Personalized Patient Drug Dosing Regimens NS Berry US Patent App. 14/535,973, 2015 | 2 | 2015 |
| Using Monte Carlo Simulations to Assess Dosing Regimen Adjustments of Piperacillin/Tazobactam in Obese Patients with Varying Renal Functions TP Dumitrescu, R Kendrick, H Calvin, S Berry JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 40, S75-S76, 2013 | 2 | 2013 |
| Life Cycle Modeling and Simulation: Current Practice and Future Impact on Health Care Innovation and Delivery M O’Kelly, S Berry, D Walp, A Garrett Therapeutic Innovation & Regulatory Science 47 (2), 175-182, 2013 | 2 | 2013 |
| Model-based simulation of varied subcutaneous immune globulin (human), 20%(Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary … Z Li, T Dumas, B McCoy, NS Berry, L Yel JOURNAL OF CLINICAL IMMUNOLOGY 41 (SUPPL 1), S96-S97, 2021 | 1 | 2021 |
| Population pharmacokinetic modeling of intravenous asparaginase Erwinia chrysanthemi: impact of varied infusion rates on exposure K Zomorodi, T Dumas, S Berry, C Johnston, M Eller Blood 128 (22), 1631, 2016 | 1 | 2016 |
| Lifecycle Modeling and Simulation M O’Kelly, S Berry, D Walp, A Garrett | 1 | 2012 |
| Optimizing Dosage in Pharmacotherapy—Missing the Forest for the Trees SM Abdel‐Rahman, AJ Farrell, NS Berry, GJ Burckart Clinical Pharmacology & Therapeutics, 2024 | | 2024 |
| POPULATION PHARMACOKINETIC (PK) MODEL DEVELOPMENT AND SIMULATION FOR RECOMBINANT CRISANTASPASE PRODUCED IN PSEUDOMONAS FLUORESCENS (RC-P). T Lin, T Dumas, J Kaullen, N Berry, M Choi, K Zomorodi, J Silverman CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S93-S94, 2020 | | 2020 |
| Better Together: Examples of Biostatisticians Collaborating in Drug Development R Reeve, S Berry, B Swift Quantitative Methods in Pharmaceutical Research and Development: Concepts …, 2020 | | 2020 |
